Zacks Investment Research lowered shares of HTG Molecular Diagnostics (NASDAQ:HTGM) from a buy rating to a hold rating in a research report sent to investors on Friday.

According to Zacks, “HTG Molecular Diagnostics, Inc. is engaged in developing and marketing a technology platform which consists of instrumentation, consumables and software analytics for sample profiling applications including tumor profiling, molecular diagnostic testing and biomarker development. Its products include HTG Edge System, HTG Edge Assays and HTG Assay Direct. HTG Molecular Diagnostics, Inc. is headquartered in Tucson, Arizona. “

A number of other equities research analysts have also weighed in on the company. Canaccord Genuity boosted their target price on HTG Molecular Diagnostics to $5.00 in a research note on Friday. HC Wainwright set a $6.00 target price on HTG Molecular Diagnostics and gave the company a buy rating in a research note on Friday. Finally, ValuEngine raised HTG Molecular Diagnostics from a strong sell rating to a sell rating in a research note on Monday, October 23rd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company. HTG Molecular Diagnostics has an average rating of Hold and an average price target of $4.88.

Shares of HTG Molecular Diagnostics (NASDAQ HTGM) opened at $3.47 on Friday. HTG Molecular Diagnostics has a 52 week low of $1.20 and a 52 week high of $13.25.

An institutional investor recently raised its position in HTG Molecular Diagnostics stock. Vanguard Group Inc. raised its holdings in shares of HTG Molecular Diagnostics Inc (NASDAQ:HTGM) by 38.9% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 135,234 shares of the medical research company’s stock after purchasing an additional 37,841 shares during the period. Vanguard Group Inc. owned 1.42% of HTG Molecular Diagnostics worth $359,000 at the end of the most recent reporting period. 15.15% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “HTG Molecular Diagnostics (HTGM) Downgraded by Zacks Investment Research to “Hold”” was reported by Daily Political and is owned by of Daily Political. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this piece of content can be read at https://www.dailypolitical.com/2018/01/06/htg-molecular-diagnostics-htgm-downgraded-by-zacks-investment-research-to-hold.html.

HTG Molecular Diagnostics Company Profile

HTG Molecular Diagnostics, Inc is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.

Receive News & Ratings for HTG Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.